Changes in lung function and chylous effusions in patients with lymphangioleiomyomatosis treated with sirolimus. - Wikidata - awgldk - TriplyDB

Changes in lung function and chylous effusions in patients with lymphangioleiomyomatosis treated with sirolimus.

Changes in lung function and chylous effusions in patients with lymphangioleiomyomatosis treated with sirolimus.

http://www.wikidata.org/entity/Q34194187

about

Optimizing treatments for lymphangioleiomyomatosis Lymphangioleiomyomatosis: differential diagnosis and optimal management Management of lymphangioleiomyomatosis Clinical features, epidemiology, and therapy of lymphangioleiomyomatosis Uterine-specific loss of Tsc2 leads to myometrial tumors in both the uterus and lungs.Diffuse Cystic Lung Disease. Part I.Protein-losing Enteropathy Caused by Intestinal or Colonic Lymphangiectasia Complicated by Sporadic Lymphangioleiomyomatosis: A Report of Two Cases.A quantitative proteomic approach to identify significantly altered protein networks in the serum of patients with lymphangioleiomyomatosis (LAM).Progress in the treatment of lymphangioleiomyomatosis: from bench to bedside.Recovery of chylous pulmonary congestion in tuberous sclerosis complex-associated lymphangioleiomyomatosis.Lymphatics in lymphangioleiomyomatosis and idiopathic pulmonary fibrosis Retrospective review of combined sirolimus and simvastatin therapy in lymphangioleiomyomatosis Sustained effects of sirolimus on lung function and cystic lung lesions in lymphangioleiomyomatosis.Antibody αPEP13h reacts with lymphangioleiomyomatosis cells in lung nodules.Management of refractory chylothorax in pulmonary lymphangioleiomyomatosis.Use of sirolimus in the treatment of lymphangioleiomyomatosis: favorable responses in patients with different extrapulmonary manifestations Recognition of tuberous sclerosis in adult women: delayed presentation with life-threatening consequences.Women with TSC: Relationship between Clinical, Lung Function and Radiological Features in a Genotyped Population Investigated for Lymphangioleiomyomatosis.Effect of fasting on the size of lymphangioleiomyomas in patients with lymphangioleiomyomatosis.Improvement of tuberous sclerosis complex (TSC) skin tumors during long-term treatment with oral sirolimus Lymphangioleiomyomatosis - a wolf in sheep's clothing.mTOR Inhibitors in Tuberous Sclerosis Complex.Lymphangioleiomyomatosis: current and future.Effects of combining rapamycin and resveratrol on apoptosis and growth of TSC2-deficient xenograft tumors.Monitoring of nonsteroidal immunosuppressive drugs in patients with lung disease and lung transplant recipients: American College of Chest Physicians evidence-based clinical practice guidelines Estrogen maintains myometrial tumors in a lymphangioleiomyomatosis model A Novel Quantitative Computed Tomographic Analysis Suggests How Sirolimus Stabilizes Progressive Air Trapping in Lymphangioleiomyomatosis.Is mTOR inhibition a systemic treatment for tuberous sclerosis?Sirolimus decreases circulating lymphangioleiomyomatosis cells in patients with lymphangioleiomyomatosis.Dramatic response to sirolimus in lymphangioleiomyomatosis.A Case of Successful Therapy by Intrapleural Injection of Fibrin Glue for Chylothorax after Lung Transplantation for Lymphangioleiomyomatosis.Pelvic lymphangioleiomyomatosis treated successfully with everolimus: Two case reports with literature review.Recent Advances and Challenges of mTOR Inhibitors Use in the Treatment of Patients with Tuberous Sclerosis Complex.The next breakthrough in LAM clinical trials may be their design: challenges in design and execution of future LAM clinical trials.Lymphangioleiomyomatosis: New Treatment Perspectives.mTOR treatment in lymphangioleiomyomatosis: the role of everolimus.Diagnosis and treatment of cystic lung disease.Tsc2 disruption in mesenchymal progenitors results in tumors with vascular anomalies overexpressing Lgals3.Rapamycin reversal of VEGF-C-driven lymphatic anomalies in the respiratory tract.In pulmonary lymphangioleiomyomatosis expression of progesterone receptor is frequently higher than that of estrogen receptor.

P2860

Q26865250-452ECD96-5A95-4711-9AE2-78294BABAA1D Q27022412-F2EBA2EC-A680-405D-B1B0-24BF149A23B9 Q28084725-B0F55EDA-6943-44B4-81F7-5BE10677CDFA Q28084975-28D9F507-929F-43BD-BFB3-38FB1F58B7EA Q30411083-C9E03DFE-FAD9-4EA5-BCBF-4B84DB7C7F9F Q33722950-CC6FD1A4-AF63-4524-AC7A-F45ABE98DF1E Q33781141-03455833-11D2-4C92-BC75-82DB41F9A249 Q34061748-E5364BF4-0A99-4F25-861E-CC6F9F8687A9 Q34079459-38477CA8-BD31-4ED6-A0B0-A0E356330072 Q34365375-1CE3A2A1-0957-4AE9-B99D-0C0A6458D9FE Q34560457-7D92583F-AAD9-427E-B98A-522726C16C79 Q34840298-4DAB55A8-04F7-4CAD-A8FF-A5C3C48B1683 Q35044713-E174DCDF-262D-44B8-A73F-A14829A17C97 Q35140982-4B634557-0EBD-444E-BADE-98AFD0D0D779 Q35747340-7F58FF0A-C1F8-4465-B8FB-03CD9AB01A09 Q35971499-45B05185-26C8-4334-B659-E7A7982E0CCB Q36008501-33ACBDE8-78D5-4F97-A256-B400E8EA5D73 Q36015287-29369FBF-FAC5-4F31-B78E-F1DDC02DB00D Q36125195-A8F9C918-2325-4FD3-B2E9-859CEDE610BE Q36173629-0616E062-5C15-4953-BA23-5C52F7F7DA06 Q36357766-C880BD26-FE70-4D0F-AEFA-6C05D151EBD0 Q36460639-16A68654-7F44-41EC-84D3-393699C068BC Q36542254-8B7C66E0-C6E2-415F-A76F-A6C23B5F6249 Q36549186-C7372277-ECAF-452D-9349-B23EF79213F5 Q36724093-A85B2BE4-F726-4334-8E00-A2D36F290D23 Q37193373-B0B32A04-1AE1-40D0-9706-3E4AC311E0A8 Q37241549-69D47908-51F5-4F42-AE24-E4415A8230AE Q37359517-12CDE71C-9D83-4B10-BBFA-AA4C95B4D7F2 Q37443410-2465510B-F863-4260-8B61-4781A6211EDC Q37567969-B467502A-191C-4464-97F6-44B76901E55B Q37695850-B0F2FA9E-0954-4EEE-8340-0572C9317D8A Q37696810-51BB91BF-715D-4351-A8F8-2CBA0C2FBEBC Q37721031-4EB93F85-BBA2-480E-BD03-1809A653581D Q38372196-0299B9BC-4EE4-4505-9815-9FAD9838617B Q38484497-F527C860-0F6C-44F0-A6DC-04B73AA192BA Q38723770-818E1959-D2A6-4F68-AC54-C2CFD226BD7D Q39164137-6717B3B3-7BCD-47FF-B772-4F2D6CB8E168 Q40984224-0C9F55D9-174D-4EED-9AE6-B752AA60E74A Q41970819-F5287E7B-2A66-4DBD-AA96-B101B790F4A2 Q42645301-BB70A7FF-1142-4DE7-A7E5-D42DD77A9203

P2860

Changes in lung function and chylous effusions in patients with lymphangioleiomyomatosis treated with sirolimus.

http://www.wikidata.org/entity/Q34194187

description

2011 nî lūn-bûn

@nan

2011 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Changes in lung function and c ...... atosis treated with sirolimus.

@ast

Changes in lung function and c ...... atosis treated with sirolimus.

@en

Changes in lung function and c ...... atosis treated with sirolimus.

@nl

type

label

Changes in lung function and c ...... atosis treated with sirolimus.

@ast

Changes in lung function and c ...... atosis treated with sirolimus.

@en

Changes in lung function and c ...... atosis treated with sirolimus.

@nl

prefLabel

Changes in lung function and c ...... atosis treated with sirolimus.

@ast

Changes in lung function and c ...... atosis treated with sirolimus.

@en

Changes in lung function and c ...... atosis treated with sirolimus.

@nl

P1433

Q34194187-33775FA0-B2B8-4CBD-95DE-ED77C27DD188

P1476

Q34194187-88441970-3F6E-4DF4-ACCA-AA74D1A02C44

P2093

Q34194187-1621A96A-05DD-4974-B593-EBEE5533EFF5

Q34194187-17427F84-6578-4067-B39B-06288D234E2A

Q34194187-174F1546-8AF7-4C15-98C4-AF37C136960B

Q34194187-EB5592AF-6700-4789-B5E3-40C678E11B76

P2860

Q34194187-14D312E3-E11B-41AA-9FED-E6B1B6FEB0E5

Q34194187-1600E79D-AE38-45DA-9BAD-CB6B32F2318A

Q34194187-16466477-0FB1-4545-B21E-09B041DB96D6

Q34194187-18212074-0D6B-4A15-B625-529006CDB277

Q34194187-18C4544F-EED8-483E-9A84-2FF1BFE1E5AF

Q34194187-1D18A039-4C15-4FCD-BBE1-A0278922E629

Q34194187-260E1F93-78C6-43F7-97B6-9B6745289E35

Q34194187-26C828F8-2248-47E4-8DC3-67CAD71F7252

Q34194187-2EA8C872-586B-41BD-AD9F-6BE6489801BB

Q34194187-35BDF3A1-D9EA-48C1-8B24-7DF337C168B1

P304

Q34194187-F779B18E-C2A6-4090-AA4D-AF6A402A306B

P31

Q34194187-36A34D2B-A8A0-469F-A79E-F79A068FF283

P356

Q34194187-59FBB6E9-D151-4FA8-AD8A-149B4038124F

P407

Q34194187-A5B0F1CD-DE64-465D-99C8-25B00283513F

P433

Q34194187-11EA0311-8135-4053-BEC8-B3EAFD4D7ABF

P478

Q34194187-D2095193-5FC2-458C-9C69-45099D36347D

P577

Q34194187-159B42DD-E57A-4BAE-B088-BA453D7A5FA8

P698

Q34194187-EA44B069-67EF-47A5-9A7E-1ED1E4C69407

P921

Q34194187-3AA892FA-6A9F-4FCA-A6B3-DCABB88AED08

P932

Q34194187-0970313B-DDEC-4AA6-AC7A-8D0FC993BB9E

P356

0003-4819-154-12-201106210-00007

P1433

Annals of Internal Medicine

P1476

Changes in lung function and c ...... atosis treated with sirolimus.

@en

P2093

Angelo M Taveira-DaSilva

http://www.w3.org/2001/XMLSchema#string

Joel Moss

http://www.w3.org/2001/XMLSchema#string

Mario Stylianou

http://www.w3.org/2001/XMLSchema#string

Olanda Hathaway

http://www.w3.org/2001/XMLSchema#string

P2860

The TSC1 tumour suppressor hamartin regulates cell adhesion through ERM proteins and the GTPase Rho

Tuberous sclerosis complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling

Efficacy and safety of sirolimus in lymphangioleiomyomatosis.

Identification and characterization of the tuberous sclerosis gene on chromosome 16

Standardisation of the single-breath determination of carbon monoxide uptake in the lung

Tuberin regulates p70 S6 kinase activation and ribosomal protein S6 phosphorylation. A role for the TSC2 tumor suppressor gene in pulmonary lymphangioleiomyomatosis (LAM)

Tuberous sclerosis complex gene products, Tuberin and Hamartin, control mTOR signaling by acting as a GTPase-activating protein complex toward Rheb

Standardisation of spirometry

Involvement of lymphatics in lymphangioleiomyomatosis

High frequency of pulmonary lymphangioleiomyomatosis in women with tuberous sclerosis complex.

P304

797-805, W-292-3

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.7326/0003-4819-154-12-201106210-00007

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

154

http://www.w3.org/2001/XMLSchema#string

P577

2011-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21690594

http://www.w3.org/2001/XMLSchema#string

P921

P932

3176735

http://www.w3.org/2001/XMLSchema#string